Pamidronate and biochemical markers of bone turnover

References

• Demers L M, Kleerokoper M. Recent advances in biochemical markers of bone turnover. Clin Chem 1994; 40: 1994–5
   PubMed Web of Science ®Google Scholar
• Eriksen E F, Brixen K, Charles P. New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 1995; 132: 251–63
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Gineyts E, Chapuy M C, Delmas PD. Urinary excretion of pyridinium cross-links a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8: 87–96
   PubMedGoogle Scholar
• Seibel M J, Cosmant F, Gordons S V, Dempster D W, Ratcliffe A, Lindsay R. Urinary hydroxypy-ridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 881–9
   PubMed Web of Science ®Google Scholar
• Seibel M J, Gortenberg F, Silverberg S J, Rateeliffe A, Robins S P, Bilerickian JP. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Melab 1992; 74: 483–6
   Google Scholar
• Alvarez Guanˆ L, Tabens Peris NP., et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10: 458–65
   Google Scholar
• Pecherstorfer M, Zimmer-Roth I, Schilling F., et al. Fhe diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase. and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995; 80: 97–103
   PubMed Web of Science ®Google Scholar
• Delmas P D, Schlemmer A, Gyneyts E, Riis B. Urinary excretion of pyridinoline correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6: 639–44
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Schlemmer A, Johansen JS., et al. Effects of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991; 72: 367–73
   PubMed Web of Science ®Google Scholar
• Fledelius C, Riis B J, Overgaard K, Christiansen C. The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosis. Calcif Tissue Int 1994; 54: 381–4
   PubMed Web of Science ®Google Scholar
• Seyedyn S M, Kung V T, Daniloff Y N, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993; 8: 635–41
   Google Scholar
• Delmas P D, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay for pyridinoline cross-link excretion in normal adults and in Paget disease. J Bone Miner Res 1993; 8: 643–8
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih W J, Gyneils E, Karpf D B, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700
   PubMed Web of Science ®Google Scholar
• Garnero P, Gyneits E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641–9
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates in osteoporosis: an introduction. Osteoporosis Int 1993; 3: S3–S5
   Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, Akins R, Simmons H. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• O'Doherty D P, McCloskey E V, Vasikaran S, Khan S, Kanis JA. The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res 1995; 10: 1094–100
   PubMedGoogle Scholar
• Siris ES. Perspectives: A practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res 1994; 9: 303–4
   Google Scholar
• Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 1994; 74: 2949–55
   PubMed Web of Science ®Google Scholar
• Kanis G A, Gertz B J, Singer F, Ortonali S. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int 1995; 5: 1–13
   PubMed Web of Science ®Google Scholar
• Blumsohn K E, Naylor K E, Assiri A, del MA, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 1995; 41: 1582–98
   Google Scholar
• Rosen H N, Dresner-Pollak R, Moses A C, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26–9
   PubMed Web of Science ®Google Scholar
• Schlemmer A, Hasseger C, Jensen S B, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74: 476–80
   PubMed Web of Science ®Google Scholar
• Martínez ME. Ionic calcium levels during pregnancy at delivery and in the first hours of life. Scand J Clin Lab Invest 1986; 46: 27–30
   PubMed Web of Science ®Google Scholar
• Goziotu A, Sukhu B, Torontate M, Dowhaniuk M, Terenbaum HC. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 1995; 16: 317S–27S
   Google Scholar
• Devlin R D, Retallack R W, Fenton A J, et al. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone. J Bone Miner Res 1994; 9: 81–5
   Google Scholar
• Filipponi P, Pedetti M, Beghe F, Giovagnini B, Miam M, Cristallini S. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. Bone 1994; 15: 261–7
   Google Scholar
• Pedrazzoni M, Alfano F S, Gatti C, Fantuzzi M, Girasole G, Campanini C., et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995; 57: 25–9
   Google Scholar
• Pappapoulus S E, Frolich M, Mudde A H, Harinck H IJ, Berg H VD, Bijvoet O LM. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab 1987; 65: 89–94
   Google Scholar
• Parthemore J G, Burton D W, Deftos LJ. Associations and dissociations between serum bone gla protein and alkaline phosphatase in skeletal metabolism. J Orthop Res 1993; 11: 671–6
   Google Scholar
• Skjodt H, Gallagher J A, Beresford J N, Coach M, Poser J W, Russell R GG. Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. J Endocr 1985; 105: 391–6
   PubMed Web of Science ®Google Scholar